Table 2.
Laboratory findings of patients infected with COVID-19 on admission.
| Normal range | All patients (n = 82) | Hypertension group (n = 29) | Nonhypertension group (n = 53) | Z | P | |
|---|---|---|---|---|---|---|
| Blood routine tests | ||||||
| WBC, × 109/L | 3.5–9.5 | 4.7 (3.5–6.7) | 4.9 (3.7–7.4) | 4.5 (3.3–6.6) | − 1.093 | 0.274 |
| Neutrophil counts, × 109/L | 1.8–6.3 | 3.2 (2.2–5.2) | 3.9 (2.7–6.3) | 3.1 (2.2–4.9) | − 1.544 | 0.122 |
| N (%), | 40–75 | 76.0 (63.8–84.3) | 79.3 (69.2–85.7) | 71.6 (62.9–83.4) | − 1.852 | 0.064 |
| Lymphocyte counts, × 109/L | 1.1–3.2 | 0.8 (0.6–1.1) | 0.72 (0.59–0.10) | 0.81 (0.56–1.26) | − 0.652 | 0.515 |
| L (%) | 20–50 | 14.1 (9.1–19.2) | 12.5 (8.6–17.3) | 16.8 (12.2–21.3) | − 1.625 | 0.098 |
| Platelets, × 109/L | 125–350 | 192.0 (127.0–225.0) | 195 (165–293) | 188 (130–225) | − 0.492 | 0.623 |
| Hemoglobin, g/L | 130·0–175 | 127.0 (119.0–135.0) | 129.5 (114.8–137) | 126.5 (120–134.8) | − 0.067 | 0.947 |
| Infection-related biomarkers | ||||||
| PCT, ng/mL | 0.04–0.25 | 0.1 (0.0–0.2) | 0.07 (0.04–0.18) | 0.05(0.04–0.1) | − 1.679 | 0.093 |
| SAA, mg/L | 0.1–10 | 501.0 (111.3–102.0) | 630.1 (185.3–1010.5) | 373.5 (48.8–777.5) | − 1.509 | 0.131 |
| CRP, mg/L | 0–5 | 67.5 (27.2–102.0) | 79.2 (33.5–129.1) | 57.8 (20.4–83.1) | − 1.802 | 0.072 |
| ESR, mm/h | 0–20 | 47.8 (23.3–80.5) | 50.5 (24.9–88.0) | 47.8 (19–70) | − 0.723 | 0.470 |
| Blood biochemistry | ||||||
| AST, U/L | 8–40 | 33.6 (26.2–51.2) | 32.4 (24.2–49.8) | 34.1 (26.8–57.0) | − 0.982 | 0.326 |
| ALT, U/L | 5–35 | 26.1(17.0–40.0) | 23.0 (18.1–42.0) | 26.3 (14.7–39.4) | − 0.630 | 0.529 |
| GGT, U/L | 0–50 | 30.2 (18.0–50.6) | 29.0 (22.6–48.3) | 30.3 (16.2–55.4) | − 0.583 | 0.560 |
| Serum urea nitrogen, mmol/L | 3.5–7.2 | 4.4 (3.2–4.5) | 4.7 (3.4–5.9) | 4.2 (3.2–4.9) | − 1.324 | 0.185 |
| Serum creatinine, μmol/L | 44–120 | 60.0 (49.0–79.3) | 70.5 (51.8–80.8) | 57.0 (49.0–79) | − 1.473 | 0.142 |
| eGFR, mL/min/1.73 m2 | > 90 | 102.0 (84.0–119.3) | 77.0 (35.3–100.7) | 113.0 (91.9–125.9) | − 2.387 | 0.017 |
| Lactate dehydrogenase, U/L | 120–250 | 249.5 (200.8–353.8) | 263.0 (235–384.5) | 240.0 (193.0–318.5) | − 1.042 | 0.297 |
| Creatine kinase, U/L | 50–310 | 97.5 (55.7–179.8) | 143.0 (84.0–220.0) | 64.0 (50.0–154.0) | − 1.732 | 0.083 |
| NT-proBNP, ng/L | 25–500 | 115 (26–372) | 166 (70–1293) | 26 (20–120.5) | − 10.252 | < 0.001 |
| K, mmol/L | 3.5–5.5 | 3.7 (3.4–4.0) | 3.6 (3.5–4.1) | 3.7 (3.5–3.9) | − 0.635 | 0.525 |
| Ca, mmol/L | 2.0–2.6 | 2.1 (2.0–2.2) | 2.1 (2.0–2.1) | 2.1 (2.0–2.2) | − 0.112 | 0.911 |
| Albumin, g/L; | 40–55 | 39.0 (35.8–43.3) | 36.4 (34.6–39.9) | 40.0 (36.6–44.6) | − 2.218 | 0.026 |
| Glucose, mmol/L | 3.9–6.1 | 7.54 (6.26–9.23) | 7.8 (7.4–9.4) | 6.5 (5.5–10.0) | − 1.583 | 0.113 |
| Total bilirubin, μmol/L | 3.4–20.5 | 9.9 (8.4–13.5) | 9.8 (8.6–12.2) | 10.0 (8.0–13.8) | − 0.159 | 0.874 |
| Direct bilirubin, μmol/L | 0–6 | 3.7 (3.2–4.7) | 3.5 (3.2–4.7) | 3.9 (3.1–4.8) | − 0.817 | 0.413 |
| Total bile acid, μmol/L | 0–12 | 4.4 (2.5–6.9) | 3.8 (2.5–6.3) | 5.3 (2.5–9.1) | − 1.141 | 0.254 |
| Coagulation function | ||||||
| D-dimer, μg/mL | 0·0–1.5 | 0.5 (0.3–1.1) | 0.5 (0.3–1.0) | 0.5 (0.3–1.4) | − 0.157 | 0.875 |
| Prothrombin time, S | 9–14 | 10.4 (7.9–11.1) | 10.6 (9.7–11.1) | 10.8 (10.3–11.5) | − 1.109 | 0.267 |
| Activated partial thromboplastin time, S | 20–40 | 27.4 (11.7–31.9) | 29.7 (24.7–39.2) | 28.2 (26.9–32.0) | − 0.802 | 0.422 |
| Fibrin(-ogen) degradation products, mg/L | 0–5 | 3.7 (2.5–5.7) | 3.7 (3.0–5.5) | 3.7 (1.7–8.7) | − 0.217 | 0.828 |
Data are expressed as the median (IQR) or n/N (%), where N is the total number of patients with available data. p values comparing patients with or without hypertension are from χ2, Fisher’s exact, or Wilcoxon rank sum tests.
COVID-19 coronavirus disease 2019, IQR interquartile range, WBC white blood cell, PCT procalcitonin, SAA serum amyloid A, CRP C-reactive protein, ESR erythrocyte sedimentation rate, AST aspartate aminotransferase, ALT alanine aminotransferase, GGT glutamine transpeptidase, eGFR estimated glomerular filtration rate, NT-proBNP N-terminal pro-brain natriuretic peptide.